Microbot Medical Partners to Bring LIBERTY Robotic System to VA, Military Hospitals
MBOT sits 16% above its 52-week low of $1.6.
Summary
Microbot Medical has entered into an agreement with Lovell Government Services to expand access for its LIBERTY Endovascular Robotic System to federal healthcare systems, including the U.S. Department of Veterans Affairs, Department of Defense, and Indian Health Service. This partnership opens up potential sales to over 2,000 government facilities, including 170 medical centers that average 200 peripheral endovascular cases annually. This follows a series of positive commercialization updates for LIBERTY, including strong Q2 revenue reported in May. The agreement is expected to streamline procurement and significantly broaden the market for MBOT's key product. Activation of the LIBERTY System on Lovell's Federal Supply Schedule is anticipated in Q3 2026.
At the time of this announcement, MBOT was trading at $1.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $122.2M. The 52-week trading range was $1.60 to $4.67. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.